GlassScriptPhysician profile
Natalya Barresi
NPI 1689063935
$3,938.65
in general payments reported to CMS, 2019-2025
35 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,970 · 2022: $510 · 2024: $268 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,458.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $517.69 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $269.71 | 2021-2025 | Datroway, Calquence, Lynparza |
| Pfizer INC. | $269.38 | 2021-2025 | |
| Daiichi Sankyo INC. | $263.69 | 2021-2025 | Enhertu |
| Eisai INC. | $256.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $250.21 | 2021-2025 | Opdivo, Opdualag |
| Amgen INC. | $244.55 | 2021-2022 | |
| Puma Biotechnology, INC. | $230.88 | 2021-2025 | |
| Janssen Biotech, INC. | $212.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $166.47 | 2021-2025 | Keytruda |
| Lilly USA, LLC | $145.95 | 2021-2025 | Jaypirca, Verzenio |
| Novartis Pharmaceuticals Corporation | $133.89 | 2021-2025 | |
| Genmab U.S., INC. | $123.67 | 2021-2025 | Epkinly |
| Bayer Healthcare Pharmaceuticals INC. | $95.89 | 2021-2025 | |
| Glaxosmithkline, LLC. | $74.36 | 2021-2025 | Ojjaara |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $70.00 | 2021 | |
| Abbvie INC. | $52.39 | 2024-2025 | |
| Incyte Corporation | $52.14 | 2025 | Monjuvi |
| Celgene Corporation | $45.71 | 2025 | Opdualag, Reblozyl |
| Myovant Sciences INC. | $44.92 | 2022 | |
| Pharmaessentia USA Corporation | $41.25 | 2025 | Besremi |
| Janssen Scientific Affairs, LLC | $41.18 | 2025 | Talvey, Tecvayli, Carvykti |
| Exelixis INC. | $39.97 | 2025 | Cabometyx |
| Syndax Pharmaceuticals, INC. | $39.94 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.83 | 2025 | Ninlaro |
| Jazz Pharmaceuticals INC. | $25.88 | 2025 | |
| Emd Serono, INC. | $24.27 | 2025 | |
| Adc Therapeutics America, INC. | $23.12 | 2024 | |
| Clovis Oncology, INC. | $21.41 | 2021 | |
| Genzyme Corporation | $21.36 | 2025 | |
| Sobi, INC | $21.23 | 2025 | |
| Aveo Pharmaceuticals, INC. | $21.02 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.41 | 2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $19.51 | 2025 | Ultomiris |
| Astellas Pharma US INC | $17.47 | 2025 | Padcev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalya Barresi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.